Two TAAR1 agonists, Ulotaront (Sunovion) and Ralmitaront (Hoffmann–La Roche), already advanced into clinical trials for the treatment of several conditions including narcolepsy (20), psychosis in Parkinson’s disease (21, 22), and schizophrenia (23). The gene discussed is TAAR1; the disease is schizophrenia.